West Pharmaceutical Services, Inc. (WST)
NYSE: WST · Real-Time Price · USD
354.07
+5.47 (1.57%)
Aug 7, 2026, 4:00 PM EDT - Market closed
WST Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 564.9 | 493.7 | 492.7 | 593.4 | 585.9 | 661.8 |
Depreciation & Amortization | 181.4 | 171.4 | 155.4 | 137.3 | 120.6 | 122.3 |
Stock-Based Compensation | 32.6 | 23.8 | 18.7 | 23.3 | 23.7 | 37.5 |
Other Adjustments | 12 | -13.9 | -16.3 | 42.9 | 8.8 | -39.5 |
Change in Receivables | - | 6.9 | -58.8 | 4 | -35.6 | -123.5 |
Changes in Inventories | - | -62.8 | 42 | -13.5 | -49.8 | -86.5 |
Changes in Accounts Payable | - | 17.9 | 2.9 | 4.4 | -2.8 | 16.8 |
Changes in Other Operating Activities | -186.8 | 117.8 | 16.8 | -15.3 | 73.2 | -4.9 |
Operating Cash Flow | 662.2 | 754.8 | 653.4 | 776.5 | 724 | 584 |
Operating Cash Flow Growth | -2.14% | 15.52% | -15.85% | 7.25% | 23.97% | 23.60% |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -225.3 | -285.9 | -377 | -362 | -284.6 | -253.4 |
Cash Acquisitions | - | - | - | - | - | -2.2 |
Other Investing Activities | - | - | -1.7 | -6.7 | -3.6 | 2.5 |
Investing Cash Flow | -225.3 | -285.9 | -378.7 | -368.7 | -288.2 | -253.1 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Issued | - | - | - | 164.7 | - | - |
Long-Term Debt Repaid | -1.3 | -1.1 | -192.3 | -2.4 | -44.3 | -2.2 |
Net Long-Term Debt Issued (Repaid) | -1.3 | -1.1 | -192.3 | 162.3 | -44.3 | -2.2 |
Issuance of Common Stock | 24.9 | 18.2 | 32.7 | 51 | 28.2 | 37.1 |
Repurchase of Common Stock | -457.1 | -136.8 | -566.6 | -451.2 | -222.2 | -151.9 |
Net Common Stock Issued (Repurchased) | -432.2 | -118.6 | -533.9 | -400.2 | -194 | -114.8 |
Common Dividends Paid | -62.4 | -61.2 | -59.1 | -57 | -54.1 | -51.1 |
Other Financing Activities | - | -4.2 | -2 | - | -1.2 | - |
Financing Cash Flow | -496.7 | -185.1 | -622.6 | -459.6 | -293.6 | -168.1 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | -14.1 | 22.9 | -21.4 | 11.4 | -10.5 | -15.7 |
Net Cash Flow | -73.9 | 306.7 | -369.3 | -40.4 | 131.7 | 147.2 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 436.9 | 468.9 | 276.4 | 414.5 | 439.4 | 330.6 |
Free Cash Flow Growth | 27.01% | 69.64% | -33.32% | -5.67% | 32.91% | 10.90% |
FCF Margin | 13.13% | 15.25% | 9.55% | 14.05% | 15.22% | 11.68% |
Free Cash Flow Per Share | 6.05 | 6.45 | 3.75 | 5.50 | 5.80 | 4.33 |
Levered Free Cash Flow | 348.4 | 465.4 | 155.2 | 524.3 | 418.9 | 474 |
Unlevered Free Cash Flow | 308.2 | 424.94 | 305.36 | 308.45 | 466.77 | 438.91 |